NVCR - Zai Lab and Novocure complete enrollment in mid-stage gastric adenocarcinoma study

Zai Lab (NASDAQ:ZLAB) and Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in the phase 2 pilot trial evaluating the safety and efficacy of Tumor Treating Fields ((TTFields)) in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. The companies said that the final data collection is expected in the first half of 2022. The single-arm, open-label, multi-center study has enrolled about 30 patients in Greater China. The primary endpoint is investigator-assessed objective response rate. The protocol is designed to include 25 evaluable patients who receive at least one tumor assessment.

For further details see:

Zai Lab and Novocure complete enrollment in mid-stage gastric adenocarcinoma study